IPO SnapShot

VANTA BIOSCIENCE LTD.

IPODATE
Sep 25, 2017 TO Sep 27, 2017
LISTINGDATE
10/6/2017 12:00:00 AM
APPLY NOW
FACEVALUE
₹ 10

per share

ISSUESIZE
₹ 7.56 Cr
PRICEBAND
₹ 50

per share

MARKETLOT
3000

shares

OBJECTIVE

The objects of the Net Proceeds (as defined below) of the Issue are:1. Augmenting additional working capital requirements2. General Corporate Purposes

DON'T HAVE A DEMAT ACCOUNT

OPENDEMAT ACCOUNTAND START YOURINVESTMENTJOURNEY WITH US

OPEN AN ACCOUNT (You will receive a call & SMS from our end)
BUSINESS DESCRIPTION

OverviewVanta Bioscience Limited (VBS) is a preclinical contract research organization, offering a host of preclinical safetyassessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech,Agrochemicals, Cosmetics, and Chemical industries. In addition we also provide risk assessment services for evaluatingthe safety of the Active Pharmaceutical Ing...

ADDRESS

Address: No.02/ G/308/ G
No.3/ F F/ S F/1-20-248
Umajay Complex
Rasoolpura
Secunderabad
City: Hyderabad,
State: Telangana
Pincode: 500003
Phone: 040-6657 5454 / 2790 3226
Email: cs@vantabio.com / info@vantabio.com
Website: www.vantabio.com

LISTED AT

BSE

LEAD MANAGER

Inventure Merchant Bankers Services Pvt Ltd.

PROMOTERS

Chandrasekhar Rao Simhadri
Dopesh Raja Mulakala
Karishma Mulakala
Mohan Krishna Mulakala
Pradeep Chowdary
Sajan Kiran Mulakala
Shravan Chintapatla
Soumya Simhadri
Vyasmurti Madhavrao Shingatgeri

PROMOTER'S HOLDING

Total Share Capital

Offered to Public

-

Promoter's Holding (Pre-Issue)

Promoter's Holding (Post-Issue)

REGISTRAR

Bigshare Services Pvt Ltd
G 10 Left Wing Amruta Village
Opp: Yashoda Hospital
Raj Bhavan Road
Somajiguda
Hyderabad

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.